SCHEMBL708968

SCHEMBL708968

O=C(O)c1cc(OCc2ccccc2F)cc([N+](=O)[O-])c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 2/20 0.53
RARA P10276 1/20 0.53
RARB P10826 1/20 0.53
RARG P13631 1/20 0.53
MAOB P27338 2/20 0.49
PARP15 Q460N3 1/20 0.49
PARP14 Q460N5 1/20 0.49
PARP10 Q53GL7 1/20 0.49
LPAR1 Q92633 2/20 0.48
LPAR5 Q9H1C0 2/20 0.48
KMT2A Q03164 5/20 0.48
MEN1 O00255 4/20 0.48
ALKBH1 Q13686 1/20 0.47
ALOX5 P09917 1/20 0.45
HPD P32754 1/20 0.45
NPC1 O15118 1/20 0.44
NR4A2 P43354 1/20 0.44
RAB9A P51151 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL708969 0.87 MAOB (0.49) GCKRARARARBRARGMAOB
SCHEMBL1654034 0.86 GCK (0.66) GCKRARARARBRARGMAOB
SCHEMBL11265699 0.83 MEN1 (0.70) MAOBKMT2AMEN1ALOX5NR4A2
SCHEMBL711300 0.82 GCK (0.59) GCKRARARARBRARGMAOB
SCHEMBL14505833 0.79 GCK (0.56) GCKRARARARBRARGMAOB
SCHEMBL14505834 0.78 GCK (0.57) GCKRARARARBRARGMAOB
SCHEMBL31504334 0.77 MAOB (0.56) MAOBPARP15PARP14PARP10KMT2A
SCHEMBL4337519 0.77 MAOB (0.56) MAOBPARP15PARP14PARP10KMT2A
SCHEMBL1444784 0.76 MAOB (0.75) GCKRARARARBRARGMAOB
SCHEMBL14505832 0.75 MAOB (0.54) GCKRARARARBRARGMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK GCK 1/4885RARA 3613/4885RARB 3193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.